ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0171

A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews

Vibeke Strand1, Prajakta Masurkar2, Jennifer Reckleff3, Taylor Schwartz4, Alison Silverstein4, Jennifer Osborne4, Josie Lloyd4, Brian Leinwand4, Elaine Karis5, Fatima Barbar-Smiley6 and Karen Costenbader7, 1Stanford University, Portola Valley, CA, 2Amgen, Inc., Atlanta, GA, 3Amgen, Inc., Westlake Village, CA, 4Inovalon Insights, Bowie, MD, 5Amgen, Inc., Colts Neck, NJ, 6Amgen, Inc., Dublin, OH, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Health Services Research, Patient reported outcomes, Pharmacoepidemiology, quality of life, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: (0155–0175) Health Services Research Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes, that significantly impact patients’ lives. Despite the known increased risk of morbidity and mortality in affected populations, there has been limited research about the impact of SLE on a patient’s daily life, such as career achievements, social/leisure activities, and family dynamics. A qualitative study was conducted to examine the impact of SLE on daily life from a patient’s perspective and to develop a conceptual framework for overall impact.

Methods: A literature review was conducted to identify domains of interest to discuss in the interviews. A semi-structured interview guide was developed to gather patients’ perspectives on previously identified areas of SLE impact and identify other ways in which SLE affects daily life. Twenty adult patients with SLE consented to teleconference interviews to discuss how SLE impacted their lives. Transcripts were then analyzed to identify themes. Based on literature review and patient interviews, a preliminary conceptual framework was developed for understanding the indirect burden of SLE on patients.

Results: The literature review identified 10 domains of interest which were used as the topics of the in-depth interviews: career/education, social impact, physical activity, cost (direct/indirect), patient burden, family planning, treatment preference, clinical perspective, family burden, and mental health. Of the patients interviewed, a majority were female (95%), aged 30-39 years (40%), African American/Black (45%), and had employer-based insurance (70%) (Table 1). Over half of the patients reported ≥1 flare in the previous 12 months. Content analysis of interview transcripts revealed 8 domains based on patients’ perceptions of how SLE impacts their daily lives (percentage of patients reporting): physical activity/mobility (20%), reduced flares (15%), ability to work (10%), relationships/social life (45%), mental health (20%), fatigue (15%), inflammation/pain (20%), and direct/indirect healthcare costs (15%) (Table 2). Patients reported that the overall burden of SLE persisted despite treatment and increased with flares. The conceptual framework illustrates domains identified from the literature review and patient interviews (Figure 1). Previously studied domains included productivity, daily life, caregiver burden, and mental health. However, education, family/social lives, future planning, and other indirect costs were newly identified as domains that have not been well characterized.

Conclusion: Based on the literature review and in-depth patient interviews, a conceptual framework was developed for understanding the numerous factors contributing to the impact of SLE on patients’ lives in 8 discrete yet interrelated domains. Data reflecting the patient-centered burden of SLE in the literature are limited, especially with respect to the impact on education, family/social lives, future planning, and indirect costs. Future research should target these evidentiary gaps to better establish a holistic view of patient-centered SLE burden.

Supporting image 1

Table 1. Demographic and disease characteristics of SLE patients who were interviewed via teleconference

Supporting image 2

Table 2. Themes that emerged from in-depth patient interviews (N = 20)

Supporting image 3

Figure 1. A Conceptual Framework for Understanding the Indirect Patient Burden of SLE


Disclosures: V. Strand: Abbvie, 2, Alpine Immune Sciences, 2, Amgen, 2, Arena, 2, AstraZeneca, 2, Bayer, 2, Biosplice, 2, Bioventus, 2, Blackrock, 2, 2, BMS, 2, Boehringer Ingelheim, 2, Celltrion, 2, Chemocentryx, 2, EMD Serono, 2, Equillium, 2, Ermium, 2, Eupraxia Pharmaceuticals, 2, Flexion, 2, Galapagos, 2, Genentech/Roche, 2, Gilead, 2, GlaxoSmithKline, 2, Horizon, 2, Ichnos, 2, Inmedix, 2, Janssen, 2, Kiniksa, 2, 2, Kypha, 2, Lilly, 2, Merck, 2, MiMedx, 2, Novartis, 2, Omeros, 2, Pfizer, 2, Regeneron, 2, Rheos, 2, R-Pharm, 2, Samsung, 2, Sandoz, 2, Sanofi, 2, Scipher, 2, Setpoint, 2, Sorrento, 2, Spherix, 2, Tonix, 2, UCB, 2, Urica, 2; P. Masurkar: Amgen, 3; J. Reckleff: Amgen, 3; T. Schwartz: Amgen, 2, Life Sciences Companies, 2; A. Silverstein: Inovalon Insights, 3; J. Osborne: None; J. Lloyd: None; B. Leinwand: None; E. Karis: Amgen, Inc, 3, 11; F. Barbar-Smiley: Amgen, 3; K. Costenbader: Amgen, 2, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Eli Lilly, 2, Exagen Diagnostics, 5, Gilead, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5.

To cite this abstract in AMA style:

Strand V, Masurkar P, Reckleff J, Schwartz T, Silverstein A, Osborne J, Lloyd J, Leinwand B, Karis E, Barbar-Smiley F, Costenbader K. A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-conceptual-framework-to-characterize-the-indirect-burden-of-systemic-lupus-erythematosus-sle-findings-from-qualitative-patient-interviews/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-conceptual-framework-to-characterize-the-indirect-burden-of-systemic-lupus-erythematosus-sle-findings-from-qualitative-patient-interviews/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology